To grasp the role of LINC00578 in cancer progression, pancancer analysis was first performed in a TCGA cohort, and the results showed that the expression of LINC00578 was dramatically decreased in 15 kinds of cancers, including colon adenocarcinoma and esophageal carcinoma, and increased in 16 kinds of cancers, including pancreatic adenocarcinoma and liver hepatocellular carcinoma (Figure 1(a)). Here, LINC00578 is linked to pancreatic adenocarcinoma.